New combo aims to tackle tough lymphomas
NCT ID NCT06484920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and ATRA (a vitamin A derivative)—in 24 adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. Participants receive ATRA for three days around each of the first four treatment cycles, plus pembrolizumab every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and all-trans retinoic acid (ATRA)
- What this could lead to
- If it works, this could offer a new treatment option for people with relapsed or refractory lymphoma that hasn't responded to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Sidney and Lois Eskenazi Hospital
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
- New pill targets Hard-to-Treat lymphoma in early human test
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?